ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 117 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2022. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,985 | -22.7% | 12,308 | -12.4% | 0.00% | – |
| Q2 2023 | $32,332 | -12.5% | 14,057 | +15.2% | 0.00% | – |
| Q1 2023 | $36,960 | +30.0% | 12,198 | 0.0% | 0.00% | – |
| Q4 2022 | $28,421 | +23.6% | 12,198 | 0.0% | 0.00% | – |
| Q3 2022 | $23,000 | -17.9% | 12,198 | +16.5% | 0.00% | – |
| Q2 2022 | $28,000 | +16.7% | 10,466 | +31.6% | 0.00% | – |
| Q1 2022 | $24,000 | -4.0% | 7,951 | +21.9% | 0.00% | – |
| Q4 2021 | $25,000 | -10.7% | 6,525 | 0.0% | 0.00% | – |
| Q3 2021 | $28,000 | +47.4% | 6,525 | +4.6% | 0.00% | – |
| Q2 2021 | $19,000 | +72.7% | 6,241 | +18.9% | 0.00% | – |
| Q2 2019 | $11,000 | -42.1% | 5,247 | 0.0% | 0.00% | – |
| Q1 2019 | $19,000 | -82.6% | 5,247 | -81.5% | 0.00% | – |
| Q4 2018 | $109,000 | -53.0% | 28,407 | +15.8% | 0.00% | – |
| Q3 2018 | $232,000 | +510.5% | 24,540 | +367.7% | 0.00% | – |
| Q2 2018 | $38,000 | – | 5,247 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 260,000 | $866,000 | 0.34% |
| RTW INVESTMENTS, LP | 5,978,355 | $19,908,000 | 0.31% |
| GSA CAPITAL PARTNERS LLP | 309,839 | $1,032,000 | 0.17% |
| QCM Cayman, Ltd. | 12,728 | $42,000 | 0.13% |
| COWEN AND COMPANY, LLC | 486,717 | $1,621,000 | 0.11% |
| Hudson Bay Capital Management LP | 1,400,000 | $4,662,000 | 0.06% |
| Kerrisdale Advisers, LLC | 208,150 | $693,000 | 0.05% |
| Secure Asset Management, LLC | 10,000 | $33,000 | 0.02% |
| PDT Partners, LLC | 72,500 | $241,000 | 0.02% |
| Point72 Asset Management, L.P. | 1,037,700 | $3,456,000 | 0.02% |